|

Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma

RECRUITINGSponsored by Azienda USL Reggio Emilia - IRCCS
Actively Recruiting
SponsorAzienda USL Reggio Emilia - IRCCS
Started2024-06-14
Est. completion2027-12-31
Eligibility
Age18 Years – 99 Years
SexFEMALE
Healthy vol.Accepted

Summary

This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.

Eligibility

Age: 18 Years – 99 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of primary leiomyosarcoma of the ovary;
* Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available.
* Aged between 18 and 99 years

Exclusion Criteria:

\- All patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibrosarcomas, stromal cell sarcomas) and patients diagnosed with leiomyosarcoma of the uterus will be excluded.

Conditions2

CancerPrimary Ovarian Leiomyosarcoma

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.